- In-Vitro Fertilization
- Preimplantation Genetic Diagnosis
- Intra-cytoplasmic Sperm injection
- Artificial Insemination
- Intracervical Insemination
- Intrauterine Insemination
- Others
- Surrogacy
- Others
Assisted Reproductive Technology (ART) Market size was valued at USD 26.22 billion in 2022 is poised to grow at a significant CAGR of 8.4% from 2023-2029. Assisted Reproductive Technology (ART) is a treatment for infertility, performed to achieve the childbirth. ART procedures include stimulation of ovaries to increase the egg production or artificial insemination or combining the sperms and eggs in the laboratory (in vitro) and embryo is transferred to woman to attain the pregnancy.Asia Pacific assisted reproductive technology (ART) market expected to account for significant share due to rise in infertility cases, late family planning, and availability of technologically advanced fertility services in the region. Latin America assisted reproductive technology market has a notable share in global market owing to expansion of business by the companies, rise in awareness about infertility treatment, and rise in healthcare expenditure are bolster the market. Middle East and Africa assisted reproductive technology market is poised to grow over forecast period owing to economic growth in the Middle East countries and increase in the infertility due to malnutrition in women are expected to upsurge the revenue of market. Obesity and the adoption of bad dietary habits, such as drinking alcohol and smoking, play a significant role in infertility. According to the American Pregnancy Association, infertility affects 30% of men and accounts for about one-fifth of all infertility cases. According to the Centers for Disease Control and Prevention (CDC), 12.1 percent of women between the ages of 15 and 44 are unable to conceive. As a result, an increase in the prevalence of infertility around the world will be a major driving force behind the use of assisted reproductive technologies.
Assisted Reproductive Technology (ART) Market Summary
Study Period
2021-2027
Base Year
2020
CAGR
8.4%
Largest Market
North America
Fastest Growing Market
Europe
Assisted Reproductive Technology (ART) Market Dynamics
Increase in the number of infertility cases, government initiations to address the infertility incidences, high disposable income in developed countries, increase in population with obesity and mental stress due to change in lifestyle, and rise in consumption of tobacco and alcohol are anticipated to propel the assisted reproductive technology (ART) market over the forecast years. However, high risk of birth defects, high cost of treatment, dearth of skilled professional in underdeveloped countries, and ethical issues may hamper the growth of assisted reproductive technology (ART) market.
North-America got significant share
Assisted Reproductive Technology (ART) Market Regional Analysis
Geographically, global Assisted Reproductive Technology (ART) market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa regions. North America assisted reproductive technology marketgrowth driven by high awareness about assisted reproductive technology among U.S. population, government support for the infertility treatment, rise in prevalence of obesity and stress due to change in lifestyle. Europe assisted reproductive technology market expected to present lucrative growth owing to adoption of newer technologies for infertility treatment, high success rate in assisted reproductive technology, and increase in the prevalence of infertility Spain, Russia, U.K., and Germany.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The assisted reproductive technology (ART) market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Assisted Reproductive Technology (ART) Market Segmentation
By Technology
By Procedure
- Fresh Non donor
- Fresh Donor
- Frozen Non Donor
- Frozen Donor
- Embryo Banking
By End User
- Hospitals
- Fertility Clinics
- Others
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East and Africa
LOCATION
Geography
Frequently Asked Questions
The key segments covered in the Assisted Reproductive Technology (ART) Market are technology, components, application, and end-users.
The Assisted Reproductive Technology (ART) Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Assisted Reproductive Technology (ART) Market key players Irvin Scientific (U.S.), Origio A/S (Denmark), Microm UK Ltd (U.K.), Parallabs Ltd (U.K.), Cryolab Ltd. (U.K.), Merck KGaA (Germany), Vitrolife AB (Sweden)
| 1.Executive Summary |
| 2.Global Assisted Reproductive Technology (ART) Market Introduction |
| 2.1.Global Assisted Reproductive Technology (ART) Market - Taxonomy |
| 2.2.Global Assisted Reproductive Technology (ART) Market - Definitions |
| 2.2.1.Technology |
| 2.2.2.Procedure |
| 2.2.3.End User |
| 2.2.4.Region |
| 3.Global Assisted Reproductive Technology (ART) Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Assisted Reproductive Technology (ART) Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Assisted Reproductive Technology (ART) Market By Technology, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. In-Vitro Fertilization |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Artificial Insemination |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Surrogacy |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Assisted Reproductive Technology (ART) Market By Procedure, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Fresh Non donor |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Fresh Donor |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Frozen Non Donor |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Frozen Donor |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Embryo Banking |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Assisted Reproductive Technology (ART) Market By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Fertility Clinics |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Assisted Reproductive Technology (ART) Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Assisted Reproductive Technology (ART) Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.In-Vitro Fertilization |
| 9.1.2.Artificial Insemination |
| 9.1.3.Surrogacy |
| 9.1.4.Others |
| 9.2. Procedure Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Fresh Non donor |
| 9.2.2.Fresh Donor |
| 9.2.3.Frozen Non Donor |
| 9.2.4.Frozen Donor |
| 9.2.5.Embryo Banking |
| 9.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospitals |
| 9.3.2.Fertility Clinics |
| 9.3.3.Others |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Assisted Reproductive Technology (ART) Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.In-Vitro Fertilization |
| 10.1.2.Artificial Insemination |
| 10.1.3.Surrogacy |
| 10.1.4.Others |
| 10.2. Procedure Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Fresh Non donor |
| 10.2.2.Fresh Donor |
| 10.2.3.Frozen Non Donor |
| 10.2.4.Frozen Donor |
| 10.2.5.Embryo Banking |
| 10.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals |
| 10.3.2.Fertility Clinics |
| 10.3.3.Others |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11.Asia Pacific (APAC) Assisted Reproductive Technology (ART) Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.In-Vitro Fertilization |
| 11.1.2.Artificial Insemination |
| 11.1.3.Surrogacy |
| 11.1.4.Others |
| 11.2. Procedure Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Fresh Non donor |
| 11.2.2.Fresh Donor |
| 11.2.3.Frozen Non Donor |
| 11.2.4.Frozen Donor |
| 11.2.5.Embryo Banking |
| 11.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals |
| 11.3.2.Fertility Clinics |
| 11.3.3.Others |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Assisted Reproductive Technology (ART) Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.In-Vitro Fertilization |
| 12.1.2.Artificial Insemination |
| 12.1.3.Surrogacy |
| 12.1.4.Others |
| 12.2. Procedure Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Fresh Non donor |
| 12.2.2.Fresh Donor |
| 12.2.3.Frozen Non Donor |
| 12.2.4.Frozen Donor |
| 12.2.5.Embryo Banking |
| 12.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals |
| 12.3.2.Fertility Clinics |
| 12.3.3.Others |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Assisted Reproductive Technology (ART) Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.In-Vitro Fertilization |
| 13.1.2.Artificial Insemination |
| 13.1.3.Surrogacy |
| 13.1.4.Others |
| 13.2. Procedure Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Fresh Non donor |
| 13.2.2.Fresh Donor |
| 13.2.3.Frozen Non Donor |
| 13.2.4.Frozen Donor |
| 13.2.5.Embryo Banking |
| 13.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals |
| 13.3.2.Fertility Clinics |
| 13.3.3.Others |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Irvin Scientific (U.S) |
| 14.2.2.Origio A/S (Denmark) |
| 14.2.3.Microm UK Ltd (U.K) |
| 14.2.4.Parallabs Ltd (U.K) |
| 14.2.5.Cryolab Ltd. (U.K) |
| 14.2.6.Merck KGaA (Germany) |
| 14.2.7.Vitrolife AB (Sweden) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Irvin Scientific (U.S)
- Origio A/S (Denmark)
- Microm UK Ltd (U.K)
- Parallabs Ltd (U.K)
- Cryolab Ltd. (U.K)
- Merck KGaA (Germany)
- Vitrolife AB (Sweden)